TY - JOUR
T1 - A Case of Improvement of Refractory Acrodermatitis Continua of Hallopeau with Guselkumab
AU - Kim, Jin Ho
AU - Ha, Dae Lyong
AU - Jang, Yong Hyun
N1 - Publisher Copyright:
© 2024 Korean Dermatological Association. All rights reserved.
PY - 2024/1
Y1 - 2024/1
N2 - Acrodermatitis continua of Hallopeau (ACH) is a rare type of pustular psoriasis that causes periungual sterile pustules, paronychia, onychodystrophy, osteolysis, and atrophic skin. This condition is known for being resistant to conventional anti-psoriatic treatments. Therefore, biologies have been explored as potential management options for ACH. A 48-year-old male presented with erythematous swelling, pustular eruptions, desquamation, and nail dystrophy on his left third fingertip for a year. Despite various anti-psoriatic treatments, including 308 nm excimer laser, oral cyclosporine, acitretin, and methotrexate, the symptoms persisted. After 9 years of experiencing this condition, the patient was started on guselkumab (an interleukin-23 inhibitor), and showed significant improvement after eight injections. The patient was in good health without any adverse effects. This case report highlights the potential effectiveness of guselkumab in the treatment of refractory ACH.
AB - Acrodermatitis continua of Hallopeau (ACH) is a rare type of pustular psoriasis that causes periungual sterile pustules, paronychia, onychodystrophy, osteolysis, and atrophic skin. This condition is known for being resistant to conventional anti-psoriatic treatments. Therefore, biologies have been explored as potential management options for ACH. A 48-year-old male presented with erythematous swelling, pustular eruptions, desquamation, and nail dystrophy on his left third fingertip for a year. Despite various anti-psoriatic treatments, including 308 nm excimer laser, oral cyclosporine, acitretin, and methotrexate, the symptoms persisted. After 9 years of experiencing this condition, the patient was started on guselkumab (an interleukin-23 inhibitor), and showed significant improvement after eight injections. The patient was in good health without any adverse effects. This case report highlights the potential effectiveness of guselkumab in the treatment of refractory ACH.
KW - Acrodermatitis continua of Hallopeau, Guselkumab
UR - http://www.scopus.com/inward/record.url?scp=85186596302&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:85186596302
SN - 0494-4739
VL - 62
SP - 53
EP - 57
JO - Korean Journal of Dermatology
JF - Korean Journal of Dermatology
IS - 1
ER -